Preclinical News and Research

RSS

MR Solutions adds new 4.7T system to cryogen-free, preclinical MRI imaging family

A new addition to the cryogen-free, preclinical MRI imaging family, the 4.7T model, is now available to order. It joins the 3T and 7T systems for superior soft tissue contrast and molecular imaging research. This has been brought to the market by MR Solutions, the world’s largest independent developer and manufacturer of commercially available MRI technology.

From MR Solutions 26 Feb 2015

Scientists use graphene to target, neutralise cancer stem cells

University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells.

25 Feb 2015

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis.

25 Feb 2015

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

There are no effective available treatments for sufferers of Glioblastoma multiforme (GBM), the most aggressive and devastating form of brain tumor. The disease, always fatal, has a survival rate of only 6-18 months.

25 Feb 2015

PCF announces Challenge Awards to support research on new treatment strategies for prostate cancer

The Prostate Cancer Foundation (PCF) announces 3 new Challenge Awards to support discoveries for the treatment of lethal prostate cancer.

25 Feb 2015

Neurodegenerative disease research using NMR: an interview with Christian Griesinger

Christian Griesinger, director of the NMR-based Structural Biology department at the Max-Planck Institute for Biophysical Chemistry, talks about his research into neurodegenerative diseases using NMR to examine the dynamics of disordered proteins.

From Bruker BioSpin Group 23 Feb 2015

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors.

23 Feb 2015

RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced the submission of a Clinical Trial Application (CTA) to the German Competent Authority, the Paul-Ehrlich-Institut (PEI), requesting clearance to initiate a Phase 1 clinical trial investigating the use of RCS-01 to treat patients suffering from aged and UV-damaged skin.

23 Feb 2015

University of Tübingen, Mediso partner to develop whole body preclinical PET insert

University of Tübingen and Mediso Ltd announced today at the 4th Tübingen PET/MR Workshop to enter into a collaboration to develop a whole body preclinical PET insert based on silicon photomultiplier sensor technology. This system can be inserted into a high field (7T) preclinical MRI scanner to enable simultaneous PET/MR imaging.

23 Feb 2015

Study: Growth hormone can improve social impairment in patients with Phelan-McDermid syndrome

A growth hormone can significantly improve the social impairment associated with autism spectrum disorder (ASD) in patients with a related genetic syndrome, according to a pilot study conducted at the Icahn School of Medicine at Mount Sinai and published yesterday on Pub Med, a public database of biomedical topics maintained by the National Institutes of Health (study originally published in the December 12 issue of the journal Molecular Autism).

20 Feb 2015

IDRI Announces $4M BARDA Cooperative Agreement To Establish Adjuvant Hub

The international outbreak of Ebola in 2014 serves as a reminder for the need to be proactive in preparing for the rapid spread of any newly emerging or re-emerging infectious disease. IDRI today announces it has received $4 million in funding from the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, to develop an adjuvant manufacturing hub with both preclinical and clinical expertise to facilitate pandemic influenza preparedness in developing countries.

19 Feb 2015

Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Nanometer-sized "drones" that deliver a special type of healing molecule to fat deposits in arteries could become a new way to prevent heart attacks caused by atherosclerosis, according to a study in pre-clinical models by scientists at Brigham and Women's Hospital and Columbia University Medical Center.

19 Feb 2015

Study results pave way for new clinical trial for glioblastoma patients

Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, according to a study published in Science Translational Medicine by a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical Research.

19 Feb 2015

University of Alberta researcher named winner of A.S.P.E.N.'s 2015 Harry M. Vars Award

David Lim, MD, CM, of the University of Alberta has been named the winner of the 2015 Harry M. Vars Award by the American Society for Parenteral and Enteral Nutrition. The award is for his research on parenteral nutrition associated liver disease (PNALD) in infants, which was presented at A.S.P.E.N.'s Clinical Nutrition Week conference in Long Beach, California, February 14 to 17.

19 Feb 2015

New molecule shows promise in controlling HIV without using daily antiretroviral drugs

Scientists have created a new molecule that shows promise for controlling HIV without daily antiretroviral drugs. The molecule foils a wider range of HIV strains in the laboratory than any known broadly neutralizing HIV antibody and is more powerful than some of the most potent of these antibodies.

19 Feb 2015

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2014, including a summary of recent corporate highlights.

19 Feb 2015

TB Alliance announces initiation of first human trial of new TB drug candidate

TB Alliance has announced the start of the first human trial of a new tuberculosis (TB) drug candidate, designated TBA-354. It is the first new TB drug candidate to begin a Phase 1 clinical trial since 2009.

19 Feb 2015

UT Southwestern researchers find that acetate speeds up growth and metastasis of tumors

UT Southwestern Medical Center researchers seeking novel ways to combat cancer found that giving acetate, a major compound produced in the gut by host bacteria, to mice sped up the growth and metastasis of tumors.

18 Feb 2015

Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

Scientists at Trinity College Dublin have uncovered a marvel molecule that blocks a key driver of inflammatory diseases. The finding could meet a major unmet clinical need by inspiring new non-invasive treatments for arthritis, multiple sclerosis and Muckle-Wells syndrome, among a myriad of other inflammatory diseases.

18 Feb 2015

Astrazeneca adopts Labguru software for global management of biological research reagents

BioData, producer of Labguru, the web-based research and lab management system, today announced that the Innovative Medicines unit of global pharmaceutical business, AstraZeneca, has adopted the Labguru platform for the global management of biological reagents used in pre-clinical research.

17 Feb 2015

Preclinical News and Research

MR Solutions adds new 4.7T system to cryogen-free, preclinical MRI imaging family

Scientists use graphene to target, neutralise cancer stem cells

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

PCF announces Challenge Awards to support research on new treatment strategies for prostate cancer

Neurodegenerative disease research using NMR: an interview with Christian Griesinger

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

University of Tübingen, Mediso partner to develop whole body preclinical PET insert

Study: Growth hormone can improve social impairment in patients with Phelan-McDermid syndrome

IDRI Announces $4M BARDA Cooperative Agreement To Establish Adjuvant Hub

Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Study results pave way for new clinical trial for glioblastoma patients

University of Alberta researcher named winner of A.S.P.E.N.'s 2015 Harry M. Vars Award

New molecule shows promise in controlling HIV without using daily antiretroviral drugs

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

TB Alliance announces initiation of first human trial of new TB drug candidate

UT Southwestern researchers find that acetate speeds up growth and metastasis of tumors

Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

Astrazeneca adopts Labguru software for global management of biological research reagents

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics